SHIELD-MI Trial Provides First Clinical Evidence Targeting Intramyocardial Hemorrhage After STEMI

Keyur P. Vora, MD, FACC Lead Clinical Trial Investigator and First Author of SHIELD-MI

Late-breaking SHIELD-MI findings suggest intramyocardial hemorrhage can be a modifiable therapeutic target after reperfusion in STEMI management.

MUNICH, GERMANY, September 12, 2026 /EINPresswire.com/ -- Results from SHIELD-MI, the first clinical study to therapeutically target intramyocardial hemorrhage in ST-elevation myocardial infarction (STEMI), were presented as a Late-Breaking Clinical Trial at ESC Congress 2026 and published simultaneously in the European Heart Journal.

Rapid restoration of coronary blood flow with primary percutaneous coronary intervention (PCI) remains fundamental to STEMI care. However, reopening the blocked artery does not necessarily end myocardial injury.

In some patients, reperfusion is followed by intramyocardial hemorrhage, in which blood extravasates into severely injured myocardium. Intramyocardial hemorrhage represents the most advanced stage of myocardial injury in the staging framework incorporated into the Fifth Universal Definition of Myocardial Infarction and is associated with larger infarction, impaired ventricular recovery, and adverse cardiovascular outcomes.

SHIELD-MI was designed around a clinically important question: Can intramyocardial hemorrhage itself become a therapeutic target?

The study evaluated dexrazoxane administered during the acute management of STEMI, targeting the period in which myocardial injury continues to evolve following reperfusion.

The findings provide the first clinical evidence that intramyocardial hemorrhage can be therapeutically modified in STEMI, supporting the concept that myocardial injury after successful reperfusion may represent an additional window for therapeutic intervention.

The name SHIELD-MI reflects this concept: reperfusion restores coronary blood flow, while a complementary therapeutic strategy could potentially shield vulnerable myocardium from continued injury after the artery has been opened.

“Primary PCI saves myocardium by restoring blood flow, but our work asks what we can do for the myocardium that remains vulnerable after reperfusion,” said Keyur P. Vora, MD, MS, Advanced Imaging Cardiologist, Lead Clinical Trial Investigator and First Author of SHIELD-MI. “SHIELD-MI provides clinical evidence that intramyocardial hemorrhage can be a modifiable therapeutic target. This opens an important direction for investigating myocardial protection beyond reperfusion.”

The findings are particularly relevant as contemporary myocardial infarction care increasingly recognizes that an excellent angiographic PCI result does not necessarily mean that injury within the myocardium has stopped.

SHIELD-MI therefore represents an early step toward a different therapeutic paradigm: reperfuse the artery rapidly, then investigate whether additional treatment can protect the myocardium from evolving post-reperfusion injury.

Further studies will be required to determine whether modifying intramyocardial hemorrhage translates into improved longer-term clinical outcomes.

The complete SHIELD-MI study is available in the European Heart Journal. https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehag715/8772199

Kapil Chhatbar
Synergy Cardiovascular Research Center
email us here

Transforming the heart: novel therapies for myocardial disease and heart failure